Loading...
XHKG
6929
, Last price  
HKD
Name

OrbusNeich Medical Group Holdings Ltd

Chart & performance

D1W1MN
XHKG:6929 chart
P/E
—
P/S
—
EPS
0.05
Vol. 1Y
—
Shs. 5Y
7.43%
Rev. 5Y
15.32%
Div Yld LY
—
Div Yld TTM
—
Revenues
180m
+9.97%
96,342,00088,472,000116,462,000136,824,000153,865,000164,097,000180,454,000
Net income
42m
+5.49%
6,958,0007,071,000-4,444,00018,491,00045,073,00039,717,00041,899,000
CFO
20m
+48.92%
1,590,00012,666,00020,498,00023,431,00023,032,00013,114,00019,530,000
Dividend
Sep 18, 20260.08 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The company boasts a significant international presence, serving markets across Japan, Europe, the Middle East, Africa, the Asia Pacific region, the People's Republic of China, and the United States. Its product offerings encompass a range of essential devices, including semi-compliant and scoring balloons used for initial vessel preparation, coronary stents for implantation, non-compliant balloons designed for post-dilatation, and a variety of specialized catheters. This extensive portfolio of products addresses critical steps within percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Founded in 2001, the company is headquartered in Shatin, Hong Kong, and operates as a subsidiary of Harmony Tree Limited.
IPO date
Dec 23, 2022
Employees
Domiciled in
HK
Incorporated in
KY
Legal address
Cricket Square, Hutchins Drive
P. O. Box 2681
Grand Cayman
George Town KY1-1111
KY
Headquarters
Units 303 & 305, 3/F Building 20E
Hong Kong Science Park
Shatin, N.T.
Hong Kong, HK 000000
CN

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT